Search Result

Results for "

β-amyloid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (164) 5-HT Receptor (1) Adenosine Deaminase (2) Akt (1) Antibiotic (4) Apoptosis (11) Autophagy (7) Bacterial (11) Beta-secretase (3) Biochemical Assay Reagents (1) CaMK (1) Caspase (8) Cathepsin (1) CCR (1) CDK (3) Cholinesterase (ChE) (18) COX (2) Cyclophilin (1) DNA/RNA Synthesis (7) Drug Derivative (2) Drug Isomer (1) EGFR (2) Endogenous Metabolite (3) Environmental Pollutants (1) Epigenetic Reader Domain (3) ERK (1) FAAH (1) Fluorescent Dye (4) Fungal (5) Gap Junction Protein (1) GCGR (1) GLUT (1) Heme Oxygenase (HO) (2) HIV (2) IKK (5) Interleukin Related (5) Isotope-Labeled Compounds (6) JNK (2) Keap1-Nrf2 (9) KLF (2) MEK (1) Mitochondrial Metabolism (2) Mitophagy (5) Mixed Lineage Kinase (2) MMP (1) Monoamine Oxidase (6) mTOR (2) Necroptosis (2) Neuropeptide Y Receptor (3) NF-κB (8) NO Synthase (4) NOD-like Receptor (NLR) (5) Notch (2) Oxidative Phosphorylation (1) p38 MAPK (3) Parasite (3) Phosphodiesterase (PDE) (3) PKC (1) Potassium Channel (1) Proteasome (1) Pyk2 (1) Pyroptosis (3) Ras (1) Reactive Oxygen Species (ROS) (4) Reference Standards (12) Salt-inducible Kinase (SIK) (2) Sigma Receptor (1) Sirtuin (5) Tau Protein (4) Telomerase (1) TGF-beta/Smad (1) TGF-β Receptor (1) TNF Receptor (3) Trk Receptor (1) Tyrosinase (2) α-synuclein (3) γ-secretase (7)
By Research Areas:	Cancer (23) Cardiovascular Disease (5) Endocrinology (6) Infection (12) Inflammation/Immunology (32) Metabolic Disease (12) Neurological Disease (190)
Click Chemistry:	Alkynes (1)

216

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

115

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

GMP Molecules

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1363B

β-Amyloid (1-42), human, HFIP-treated 20+ Cited Publications	Amyloid-β	Neurological Disease
β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide *that has been treated with HFIP from β-Amyloid* (1-42), human (HY-P1363A)*, is a brain-penetrant amyloid* protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1363A

β-Amyloid (1-42), human 20+ Cited Publications amyloid β-peptide (1-42) (human)	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P1363

β-Amyloid (1-42), human TFA 20+ Cited Publications amyloid β-peptide (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42) (Amyloid β-peptide (1-42), human TFA, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human TFA remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human TFA, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-P0128

β-Amyloid (25-35) Maximum Cited Publications 42 Publications Verification amyloid beta-peptide (25-35); Aβ25-35; β-amyloid peptide (25-35)	Amyloid-β	Neurological Disease
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .

HY-P1388

β-Amyloid (1-42), (rat/mouse) 5+ Cited Publications amyloid β-peptide (1-42) (rat/mouse)	Amyloid-β	Neurological Disease
β-Amyloid (1-42), (rat/mouse) is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.

HY-14176

Compound E 15+ Cited Publications γ-Secretase-IN-1	γ-secretase	Cancer
Compound E is a γ-secretase inhibitor. Compound E blocks β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀s of 0.24, 0.37, 0.32 nM, respectively.

HY-P1362

β-Amyloid (42-1), human 1 Publications Verification amyloid β Peptide (42-1)(human)	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human is the inactive form of Amyloid β Peptide (1-42). Its active form, β-Amyloid (1-42), may play a key role in the pathogenesis of Alzheimer's disease .

HY-P0265A

β-Amyloid (1-40) (human) TFA 5+ Cited Publications amyloid β-Peptide (1-40) (human) TFA; Aβ40 (human) TFA; Aβ(1-40) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-40) TFA is a primary protein in plaques found in the brains of patients with Alzheimer's disease .

HY-P0128A

β-Amyloid (25-35), HFIP-treated Maximum Cited Publications 42 Publications Verification amyloid beta-peptide (25-35), HFIP-treated; Aβ25-35, HFIP-treated; β-amyloid peptide (25-35), HFIP-treated	Amyloid-β	Neurological Disease
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)), HFIP-treated is a β-Amyloid (25-35) (HY-P0128) treated with HFIP. β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells .

HY-P1363F3

*5-FAM-β-Amyloid* (1-42), human Tris** 5-FAM-amyloid β-peptide (1-42) (human) Tris	Amyloid-β	Neurological Disease
5-FAM-β-Amyloid (1-42), human (5-FAM-Amyloid β-peptide (1-42) (human) TFA is a5-FAM labeled β-Amyloid (1-42), human TFA (HY-P1363).

HY-P0265C

β-Amyloid (1-40), HFIP-treated TFA 5+ Cited Publications	Amyloid-β	Neurological Disease
β-Amyloid (1-40), HFIP-treated is a β-Amyloid (1-40) (HY-P0265A) treated with HFIP. β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease .

HY-117259

Valiltramiprosate 1 Publications Verification ALZ-801	Amyloid-β	Neurological Disease
ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound . ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease .

HY-P1466

β-Amyloid (1-16) amyloid β-Protein (1-16)	Amyloid-β	Neurological Disease
β-Amyloid (1-16) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P1903

β-Amyloid (35-42)	Amyloid-β	Neurological Disease
β-Amyloid (35-42) is a peptide consisting of amino acid of 35 to 42 of beta amyloid protein.

HY-P5124

β-Amyloid peptide(16-20) KLVFF	Amyloid-β	Neurological Disease
β-Amyloid peptide(16-20) is a amino acid sequences (KLVFF) of *Amyloid-β* (Abeta). β-Amyloid peptide(16-20) is an effective inhibitor of Abeta fibril formation, with RG-/-GR-NH₂ residues added at N- and C-terminal ends to aid solubility) .

HY-P3688A

β-Amyloid (1-38) TFA Aβ (1-38) TFA; Aβ38 TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-38) (Aβ (1-38)) TFA is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) TFA interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38)TFA reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .

HY-P0128F

*FITC-β-Amyloid* (25-35)**	Amyloid-β	Neurological Disease
FITC-β-Amyloid (25-35) is a FITC (HY-66019) labeled β-Amyloid (25-35) (HY-P0128)

HY-P1388A

β-Amyloid (1-42), (rat/mouse) TFA 5+ Cited Publications amyloid β-peptide (1-42) (rat/mouse) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-42), (rat/mouse) TFA is a 42-aa peptide, shows cytotoxic effect on acute hippocampal slices, and used in the research of Alzheimer's disease.

HY-P1363F1

*Biotin-β-Amyloid* (1-42), human TFA** Biotin-amyloid β-peptide (1-42) (human) TFA	Amyloid-β	Neurological Disease
Biotin-β-Amyloid (1-42), human TFA (Biotin-Amyloid β-Peptide (1-42) (human) TFA) is the botin labeled β-Amyloid (1-42), human TFA (HY-P1363). β-Amyloid (1-42), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-103374

Phenserine (-)-Eseroline phenylcarbamate; (-)-Phenserine	Cholinesterase (ChE) Amyloid-β	Neurological Disease
Phenserine ((-)-Eseroline phenylcarbamate) is a derivative of Physostigmine (HY-N6608) and is a potent, noncompetitive, long-acting and selective AChE inhibitor. Phenserine reduces β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ) formation. Phenserine improves cognitive performance and attenuates the progression of Alzheimer's disease .

HY-P2550A

β-Amyloid (1-40), FAM-labeled TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-40), FAM-labeled TFA is a FAM fluorescently-labelled β-Amyloid (1-40) peptide (λex= 492 nm and λem= 518 nm).

HY-P1387

β-Amyloid (1-40) (rat)	Amyloid-β Apoptosis	Neurological Disease
β-Amyloid (1-40) (rat) is a rat form of the amyloid β-peptide, which accumulates as an insoluble extracellular deposit around neurons, giving rise to the senile plaques associated with Alzheimer's disease (AD). β-Amyloid (1-40) (rat) increases ⁴⁵Ca ²⁺ influx, induces neurodegeneration in the rat hippocampal neurons of the CA1 subfield. β-Amyloid (1-40) (rat) induces apoptosis. β-Amyloid (1-40) (rat) can be used for the research of Alzheimer's disease .

HY-P2283

β-Amyloid (1-37) (human)	Amyloid-β	Neurological Disease
β-Amyloid (1-37) (human) correlates moderately with Mini-Mental State Examination (MMSE) scores in Alzheimer disease. β-Amyloid (1-37) (human) possesses an added diagnostic value .

HY-P1378A

β-Amyloid (1-43)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) TFA is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) TFA shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) TFA could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P1046

β-Amyloid (1-15) amyloid β-Protein (1-15)	Amyloid-β	Neurological Disease
β-Amyloid (1-15) is a fragment of β-Amyloid peptide. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-P10040

*(Gln22)β-Amyloid* (1-40) human**	Amyloid-β	Neurological Disease
(Gln22)β-Amyloid (1-40) human is an amyloid beta protein (Aβ)-containing peptide used in Alzheimer's disease research .

HY-100275

MK-3328	Amyloid-β	Neurological Disease
MK-3328 is a *β-Amyloid* ligand, which exhibits high binding potency with an IC₅₀ of 10.5 nM. MK-3328 is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging .

HY-P1047

β-Sheet Breaker Peptide iAβ5 [Pro18, Asp21] β-amyloid (17-21)	Amyloid-β	Neurological Disease
β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.

HY-P2550

β-Amyloid (1-40), FAM-labeled	Amyloid-β	Neurological Disease
β-Amyloid (1-40), FAM-labeled is a FAM fluorescently-labelled β-Amyloid (1-40) peptide (λ_ex= 492 nm and λ_em= 518 nm) .

HY-P1362F

*Cy5-β-Amyloid* (42-1), human Tris** Cy5-amyloid β Peptide (42-1)(human) Tris	Amyloid-β	Neurological Disease
Cy5-β-Amyloid (42-1), human is a Cy5 fluorescently-labelled β-Amyloid (42-1, human) peptide (λ_ex= 633 nm and λ_em= 670 nm) .

HY-P4867A

β Amyloid (1-42) (scrambled) TFA	Amyloid-β	Neurological Disease
β Amyloid (1-42) (scrambled) TFA is a negative control of β-Amyloid (1-42), human TFA (HY-P1363) .

HY-P1468

β-Amyloid (1-28) amyloid β-Protein (1-28)	Amyloid-β	Neurological Disease
β-Amyloid (1-28) is a β-Amyloid protein fragment involved in metal binding. Beta-amyloid is a peptide that forms amyloid plaques in the brains of Alzheimer's disease (AD) patients.

HY-W117986

Aβ aggregation-IN-1	Amyloid-β Reactive Oxygen Species (ROS) Caspase	Neurological Disease
Aβ aggregation-IN-1 (Compound 1b) is a *β-amyloid* aggregation inhibitor/depolymerizer, with IC₅₀ values of 3.92 μM and 7.19 μM, respectively. Aβ aggregation-IN-1 inhibits the activation of preformed *β-amyloid* fibrils, reactive oxygen species (ROS) and Caspase-3. Aβ aggregation-IN-1 can be used in research related to Alzheimer's disease .

HY-P1891

β-Amyloid (22-40)	Amyloid-β	Neurological Disease
β-Amyloid (22-40) is a peptide fragment of β-Amyloid.

HY-P1378

β-Amyloid (1-43)(human)	Amyloid-β	Neurological Disease
β-Amyloid (1-43)(human) is more prone to aggregation and has higher toxic properties than the long-known Aβ1-42. β-Amyloid (1-43)(human) shows a correlation with both sAPPα and sAPPβ. β-Amyloid (1-43)(human) could be considered an added Alzheimer's disease (AD) biomarker together with the others already in use .

HY-P1517

β-Amyloid (31-35)	Amyloid-β	Neurological Disease
β-Amyloid (31-35) is the shortest sequence of native Amyloid-β peptide that retains neurotoxic activity.

HY-P3688

β-Amyloid (1-38) Aβ (1-38); Aβ38	Amyloid-β	Neurological Disease
β-Amyloid (1-38) (Aβ (1-38)) is a β-Amyloid (Aβ) peptide. β-Amyloid (1-38) interferes with the conversion of Aβ(1-42) to a β-sheet-rich aggregate. β-Amyloid (1-38) reverses the negative impact of Aβ(1-42) on long-term potentiation in acute hippocampal slices and on membrane conductance in primary neurons, and mitigates an Aβ(1-42) phenotype in Caenorhabditis elegans .

HY-P1894

β-Amyloid Protein Precursor 770 (135-155)	Amyloid-β	Neurological Disease
β-Amyloid Protein Precursor 770 (135-155) is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42 .

HY-P1879

β-Amyloid (18-28)	Amyloid-β	Neurological Disease
β-Amyloid (18-28) is a peptide fragment of β-Amyloid.

HY-P4867

β Amyloid (1-42) (scrambled)	Amyloid-β	Neurological Disease
β Amyloid (1-42) (scrambled) is a negative control of β-Amyloid (1-42), human (HY-P1363A) .

HY-P1053

β-Amyloid (10-20)	Amyloid-β	Neurological Disease
β-Amyloid (10-20) is a fragment of Amyloid-β peptide and maybe used in the research of neurological disease .

HY-P2549

*Biotin-β-Amyloid* (1-40)**	Fluorescent Dye	Neurological Disease
Biotin-β-Amyloid (1-40) is a N-terminal-labelled biotinylated amyloid-β-(1-40) peptide.

HY-P1787

β-Amyloid (4-10)	Amyloid-β	Neurological Disease
β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model .

HY-P1051

β-Amyloid (12-28) amyloid β-Protein (12-28)	Amyloid-β	Neurological Disease
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research .

HY-P1363S

β-Amyloid-15N (1-42), human TFA amyloid β-peptide-15N (1-42) (human) TFA	Amyloid-β	Neurological Disease
β-Amyloid- ¹⁵N (1-42), human (TFA) is the ¹⁵N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-P0128F1

*FITC-β-Ala-β-Amyloid* (25-35）**	Amyloid-β	Neurological Disease
FITC-β-Ala-β-Amyloid (25-35) is a fluorescent product labeled by FITC that can be used in Alzheimer's disease research .

HY-P2562

β-Amyloid (1-38), mouse, rat	Amyloid-β	Neurological Disease
β-Amyloid (1-38), mouse, rat is composed of 38 aa (1-38 residues of the Aβ peptide) and is the primary component of the amyloid plaques of Alzheimer’s disease .

HY-P1522

β-Amyloid (29-40) amyloid beta-protein(29-40)	Amyloid-β	Neurological Disease
β-Amyloid (29-40) is a fragment of Amyloid-β peptide.

HY-P1362A

β-Amyloid (42-1), human TFA amyloid β Peptide (42-1)(human) TFA	Amyloid-β	Neurological Disease
β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-P1894A

β-Amyloid Protein Precursor 770 (135-155) TFA	Amyloid-β	Neurological Disease
β-Amyloid Protein Precursor 770 (135-155) TFA is a peptide of amyloid precursor protein isoform (APP 770). APP 770 produces Aβ40/42 .

Cat. No.	Product Name	Type

HY-P1363F3

*5-FAM-β-Amyloid* (1-42), human Tris** 5-FAM-amyloid β-peptide (1-42) (human) Tris	Fluorescent Dyes
5-FAM-β-Amyloid (1-42), human (5-FAM-Amyloid β-peptide (1-42) (human) TFA is a5-FAM labeled β-Amyloid (1-42), human TFA (HY-P1363).

HY-P1362F

*Cy5-β-Amyloid* (42-1), human Tris** Cy5-amyloid β Peptide (42-1)(human) Tris	Fluorescent Dyes
Cy5-β-Amyloid (42-1), human is a Cy5 fluorescently-labelled β-Amyloid (42-1, human) peptide (λ_ex= 633 nm and λ_em= 670 nm) .

HY-16561G

Resveratrol

trans-Resveratrol; SRT501

Fluorescent Dyes

Resveratrol (GMP) is Resveratrol (HY-16561) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-14176G

Compound E γ-Secretase-IN-1	Fluorescent Dyes
Compound E (GMP) is a GMP-grade Compound E (HY-14176). GMP-grade small molecules can be used as adjuvant reagents in cell therapy. Compound E is a γ-secretase inhibitor. Compound E inhibits β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀ values of 0.24, 0.37, and 0.32 nM, respectively .

HY-103373

PE154	Fluorescent Dyes
PE154 (Compound 13) is a potent fluorescent inhibitor of human acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) (IC₅₀s=280 pM and 16 nM, respectively) . PE154 can label β-amyloid plaques in histochemical analysis .

HY-D1684

DCDAPH	Fluorescent Dyes
DCDAPH (Compound 2c) is a novel smart NIRF probe for detection of *β-amyloid* (Aβ) plaques (λ_ex/λ_em=597/665 nm in PBS). DCDAPH shows high affinity for Aβ aggregates (K_i=37 nM, K_d=27 nM). DCDAPH shows good blood brain barrier permeation and can meet most of the requirements for the detection of Aβ plaques both in vitro and in vivo .

HY-D3220

PTO-41	Fluorescent Dyes
PTO-41 is a blood-brain barrier-permeable near-infrared fluorescent probe that targets β-amyloid oligomers (Aβ Oligomers, AβOs) with a K_d of 349 nM. PTO-41 exhibits low cytotoxicity, high sensitivity to β-amyloid oligomers in in vitro phantom imaging, and can be rapidly cleared from the brain. PTO-41 is applicable to the research of Alzheimer's disease (Ex/Em = 538 nM/680 nM) .

HY-D3430

PTPA-QM

Fluorescent Dyes

PTPA-QM is a low-cytotoxicity Aβ protein probe that can be used for live-cell imaging and tissue section staining (Lys. Ex/Em = 385/615 nm). PTPA-QM can intercalate into the β-sheet layered structure of β-amyloid fibrils, form intermolecular interactions with amino acid residues, restrict intramolecular rotation and trigger fluorescence activation for imaging purposes. PTPA-QM is applicable to Alzheimer's disease-related research. Maximum excitation/emission wavelength: 448/605 nm .

HY-16900G

Rolipram

Fluorescent Dyes

Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Cat. No.	Product Name	Type

HY-16561G

Resveratrol

trans-Resveratrol; SRT501

Biochemical Assay Reagents

HY-14176G

Compound E γ-Secretase-IN-1	Biochemical Assay Reagents
Compound E (GMP) is a GMP-grade Compound E (HY-14176). GMP-grade small molecules can be used as adjuvant reagents in cell therapy. Compound E is a γ-secretase inhibitor. Compound E inhibits β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀ values of 0.24, 0.37, and 0.32 nM, respectively .

HY-16900G

Rolipram

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area	Image

HY-P990110

Lecanemab (Mouse IGG2a) 1 Publications Verification Mab158	Amyloid-β	Neurological Disease
Lecanemab (Mouse IGG2a) (Mab158) is a monoclonal antibody that targets soluble *β-amyloid* and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .

HY-P99185

Bapineuzumab AAB-001	Amyloid-β	Neurological Disease
Bapineuzumab is an *anti-β-amyloid* protein (APP)** monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .

HY-P991413

ZEB85	Trk Receptor ERK Akt p38 MAPK	Neurological Disease Inflammation/Immunology
ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD) .

HY-P99216

Ponezumab 1 Publications Verification PF-04360365; RN 1219	Amyloid-β	Neurological Disease
Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease .

HY-P991168

Velaprumig	Amyloid-β CCR	Neurological Disease Inflammation/Immunology
Velaprumig is a monoclonal antibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities .

HY-P992157

*Anti-APP/Amyloid* beta Antibody (3D6)** murine version of Bapineuzumab	Amyloid-β	Neurological Disease
Anti-APP/Amyloid beta Antibody (3D6) is an antibody targeting β-amyloid protein (Aβ) containing free Asp1. Anti-APP/Amyloid beta Antibody (3D6) recognizes and binds to the amino acid epitope at positions 1-5 of β-amyloid protein with a free Asp1 residue. Anti-APP/Amyloid beta Antibody (3D6) serves as a detection antibody in immunoblot analysis. Anti-APP/Amyloid beta Antibody (3D6) is applicable to research related to Alzheimer's disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-16561

Resveratrol Maximum Cited Publications 160 Publications Verification trans-Resveratrol; SRT501	Structural Classification Classification of Application Fields Anti-aging Vitis vinifera cv. Zalema Plants Vitaceae Infection Functional Molecules Sunscreen Research of Health Products Phenols Polyphenols Cosmetic Research Inflammation/Immunology Disease Research Fields Source Classification Cancer	DNA/RNA Synthesis IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (trans-Resveratrol; SRT501) is a CNS-penetrant natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, *β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-N0044

Ginsenoside Re 4 Publications Verification Ginsenoside B2; Panaxoside Re; Sanchinoside Re	Panax ginseng C. A. Meyer Triterpenes Neurological Disease Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification Cancer	Amyloid-β NF-κB JNK Endogenous Metabolite
Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the *β-amyloid* protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.

HY-W050154

Kojic acid 2 Publications Verification	Infection Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Parasite Tyrosinase NF-κB CDK
Kojic acid is a substance produced by Aspergillus oryzae that is orally effective and can also be absorbed transdermally. Kojic acid exhibits various biological activities, including anti-aging, anti-nematode, antimicrobial, antioxidant, and anti-inflammatory effects. Kojic acid is a Tyrosinase inhibitor with an Mushroom Tyrosinase IC₅₀ of 182.7 μM. Kojic acid prevents melanin production by capturing copper ions that bind to the tyrosinase active site, thus inhibiting its activation. Kojic acid also suppresses the NF-κB and p21 signaling pathways in human keratinocytes. Kojic acid derivatives have anticancer activity .

HY-12688A

Succinyl phosphonate trisodium salt 10+ Cited Publications	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Endogenous metabolite Disease Research Fields Source Classification Cancer	Mitochondrial Metabolism Reactive Oxygen Species (ROS) Amyloid-β
Succinyl phosphonate trisodium salt is a α-Ketoglutarate Dehydrogenase Complex (KGDHC) modulator with neuroprotective activity. Succinyl phosphonate trisodium salt protects this complex, reduces cellular succinyl-CoA concentration, downregulates protein succinylation levels, and inhibits the activity of the α-ketoglutarate dehydrogenase complex. Succinyl phosphonate trisodium salt corrects hypoxic or ethanol-induced behavioral impairments, modulates exploratory behavior and emotional stress responses, and improves hypoxia tolerance. Succinyl phosphonate trisodium salt reduces glutamate excitotoxicity, restores the activity of the α-ketoglutarate dehydrogenase complex, reverses the changes in glutamate dehydrogenase and glutamine synthetase activities induced by β-amyloid (Amyloid-β), modulates cognitive function, and prevents β-amyloid-induced neuronal damage. Succinyl phosphonate trisodium salt improves microglial senescence, alleviates neuroinflammation, reactive oxygen species (ROS) production, lipid peroxidation, and the expression of proinflammatory cytokines. Succinyl phosphonate trisodium salt can be used in the research of Alzheimer's disease, aging-related neuroinflammation, and Parkinson's disease .

HY-W012634

Benzothiazole	Source Classification	Environmental Pollutants Bacterial
Benzothiazole is a natural occurring heterocyclic nuclei. Benzothiazole nucleus possesses a number of biological activities such as anticancer, antimicrobial, antidiabetic, anti-inflammatory, antileishmanial, and antiviral. Furthermore, Benzothiazole nucleus can function as an efficacious β-amyloid imaging agent ^[1][2][3][4].

HY-16561R

Resveratrol (Standard) Maximum Cited Publications 160 Publications Verification trans-Resveratrol (Standard); SRT501 (Standard)	Infection Functional Molecules Classification of Application Fields Sunscreen Anti-aging Research of Health Products Cosmetic Research Plants Inflammation/Immunology Disease Research Fields Source Classification Cancer	Reference Standards IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Antibiotic Keap1-Nrf2
Resveratrol (Standard) is the analytical standard of Resveratrol. This product is intended for research and analytical applications. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, *β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-N2099

Onjisaponin B 2 Publications Verification Senegin III	Triterpenes Structural Classification Neurological Disease Classification of Application Fields Terpenoids Polygalaceae Plants Polygala tenuifolia Willd. Disease Research Fields Source Classification	Autophagy Amyloid-β Caspase NF-κB Apoptosis
Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB .

HY-N7368

Hibifolin	Flavonols Flavonoids other families Neurological Disease Classification of Application Fields Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	Adenosine Deaminase Bacterial Caspase
Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (K_i = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC₅₀ = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A) .

HY-N7981

Pratensein 1 Publications Verification	Trifolium pratense L. Flavonoids Leguminosae Phenols Polyphenols Plants Isoflavones Source Classification	NF-κB
Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels .

HY-N1570

Pterosin B	Structural Classification other families Classification of Application Fields Ketones, Aldehydes, Acids Plants Pteridium aquilinum Inflammation/Immunology Disease Research Fields Pteridiaceae Source Classification	Salt-inducible Kinase (SIK) KLF Amyloid-β
Pterosin B is an orally active indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces *β-amyloid* deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .

HY-139066

Punicic acid 1 Publications Verification Trichosanic acid	Structural Classification Punica granatum L. Classification of Application Fields Ketones, Aldehydes, Acids Metabolic Disease Punicaceae Plants Disease Research Fields Source Classification	TNF Receptor GLUT Proteasome Tau Protein PKC
Punicic acid is a bioactive compound of pomegranate seed oil. Punicic acid is an isomer of conjugated α-linolenic acid and ω-5 polyunsaturated fatty acids. Punicic acid has anti-inflammatory and antioxidant activities and can inhibit the expression of inflammatory mediators such as tumor necrosis factor α (TNF-α). Punicic acid can also reduce the formation of β-amyloid deposits and hyperphosphorylation of tau by increasing the expression of GLUT4 protein and inhibiting the overactivation of calpain, and is used to prevent and treat neurodegenerative diseases. In addition, punicic acid also has breast cancer inhibitor properties that depend on lipid peroxidation and PKC pathways .

HY-N5064

Bacoside A3	Triterpenes Terpenoids Scrophulariaceae Plants Bacopa monnieri (Linn.) Wettst. Source Classification	Apoptosis NO Synthase COX
Bacoside A3 is a triterpenoid saponin isolated from Bacopa monnieri. Bacoside A3 has neuroprotective activity, downregulating β-amyloid-induced inflammatory responses and inhibiting neuronal apoptosis. Bacoside A3 can be used in the study of Alzheimer's disease .

HY-116753

(-)Clausenamide	Clausena lansium (Lour.) Skeels Rutaceae Plants Source Classification	Amyloid-β Tau Protein
(-)Clausenamide is an active alkaloid isolated from the leaves of Clausena lansium (Lour.) Skeels, and improves cognitive function in both normal physiological and pathological conditions. (-)Clausenamide inhibits *β-amyloid* (Aβ) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. (-)Clausenamide exerts a significant neuroprotective activity against Aβ_25-35. (-)Clausenamide can be used for researching Alzheimer's disease (AD) .

HY-12688

Succinyl phosphonate	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification	Mitochondrial Metabolism Reactive Oxygen Species (ROS) Amyloid-β
Succinyl phosphonate is a α-Ketoglutarate Dehydrogenase Complex (KGDHC) modulator with neuroprotective activity. Succinyl phosphonate protects this complex, reduces cellular succinyl-CoA concentration, downregulates protein succinylation levels, and inhibits the activity of the α-ketoglutarate dehydrogenase complex. Succinyl phosphonate corrects hypoxic or ethanol-induced behavioral impairments, modulates exploratory behavior and emotional stress responses, and improves hypoxia tolerance. Succinyl phosphonate reduces glutamate excitotoxicity, restores the activity of the α-ketoglutarate dehydrogenase complex, reverses the changes in glutamate dehydrogenase and glutamine synthetase activities induced by β-amyloid (Amyloid-β), modulates cognitive function, and prevents β-amyloid-induced neuronal damage. Succinyl phosphonate improves microglial senescence, alleviates neuroinflammation, reactive oxygen species (ROS) production, lipid peroxidation, and the expression of proinflammatory cytokines. Succinyl phosphonate can be used in the research of Alzheimer's disease, aging-related neuroinflammation, and Parkinson's disease .

HY-W004287

Methyl tridecanoate	Structural Classification Natural Products other families Plants Source Classification	Amyloid-β Cholinesterase (ChE) Parasite
Methyl tridecanoate is a fatty acid methyl ester. Methyl tridecanoate exhibits an IC₅₀ of 3.26 μM and a K_i of 2.30 μM against AsOBP21f in Anopheles sinensis. Methyl tridecanoate induces electroantennographic responses in female Anopheles sinensis. Methyl tridecanoate shows a dose-dependent attractive effect on Anopheles sinensis. Methyl tridecanoate weakly inhibits *β-amyloid* aggregation and AChE activity. Methyl tridecanoate can be used in the research of malaria and Alzheimer's disease .

HY-N1570R

Pterosin B (Standard)	Structural Classification other families Ketones, Aldehydes, Acids Plants Pteridium aquilinum Pteridiaceae Source Classification	Reference Standards Salt-inducible Kinase (SIK) KLF Amyloid-β
Pterosin B (Standard) is the analytical standard of Pterosin B (HY-N1570). This product is intended for research and analytical applications. Pterosin B is an indanone. Pterosin B can be obtained from Pteridium aquilinum. Pterosin B is a Sik3 signaling inhibitor. Pterosin B inhibits Klf5 expression and reduces *β-amyloid* deposition. Pterosin B prevents chondrocyte hypertrophy and osteoarthritis in mice. Pterosin B inhibits cardiomyocyte hypertrophy, improves cognitive impairment, and lowers blood glucose. Pterosin B can be used in research on arthritis, Alzheimer's disease, pathological cardiac hypertrophy and diabetes .

HY-N2099A

(Z)-Onjisaponin B (Z)-Senegin III	Triterpenes Structural Classification Polygala senega L. Terpenoids Polygalaceae Plants Pentacyclic Triterpenoids Source Classification	Drug Derivative
(Z)-Onjisaponin B ((Z)-Senegin III) is a derivative of Onjisaponin B (HY-N2099). Onjisaponin B is an orally active natural product derived from Polygala tenuifolia. Onjisaponin B inhibits NF-κB p65. Onjisaponin B enhances autophagy and accelerates the degradation of mutant α-synuclein and huntingtin. Onjisaponin B reduces β-amyloid (Aβ) production. Onjisaponin B reduces radiation-induced cell apoptosis. Onjisaponin B has anti-oxidant and anti-inflammatory activities. Onjisaponin B can be used for neurological disease and radiation injury study, and its metabolite tenuifolin (TF) can enter the brain through the BBB .

HY-W050154R

Kojic acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Parasite Tyrosinase NF-κB CDK
Kojic acid (Standard) is the analytical standard of Kojic acid. This product is intended for research and analytical applications. Kojic acid is a substance produced by Aspergillus oryzae, with various biological activities including antitumor, insecticidal, antibacterial, antioxidant, and radioprotective effects. Kojic acid exhibits tyrosinase inhibition activity by capturing copper ions that bind to the active site of tyrosinase, preventing its activation. Tyrosinase is a key enzyme in the biosynthesis of melanin, so kojic acid can block melanin production. Additionally, kojic acid shows potential inhibition of NF-κB activity in human keratinocytes, which may also be related to the anti-melanogenic effect induced by kojic acid. Kojic acid is effective when administered orally and can also be absorbed transdermally. Nano-carrier systems prepared with kojic acid demonstrate effective delivery of anticancer drugs. Kojic acid holds promise for research in cancer, infectious diseases, and skin whitening among other fields .

HY-W004287R

Methyl tridecanoate (Standard)	Structural Classification Natural Products other families Plants Source Classification	Reference Standards Amyloid-β Cholinesterase (ChE)
Methyl tridecanoate (Standard) is the analytical standard of Methyl tridecanoate. This product is intended for research and analytical applications. Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE) .

HY-N0044R

Ginsenoside Re (Standard) Ginsenoside B2(Standard); Panaxoside Re(Standard); Sanchinoside Re (Standard)	Panax ginseng C. A. Meyer Neurological Disease Classification of Application Fields Terpenoids Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification Cancer	Reference Standards Amyloid-β NF-κB JNK Endogenous Metabolite
Ginsenoside Re (Standard) is the analytical standard of Ginsenoside Re. This product is intended for research and analytical applications. Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the *β-amyloid* protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.

HY-W012634R

Benzothiazole (Standard)	Microorganisms Source Classification	Reference Standards Bacterial
Benzothiazole (Standard) is the analytical standard of Benzothiazole. This product is intended for research and analytical applications. Benzothiazole is a natural occurring heterocyclic nuclei. Benzothiazole nucleus possesses a number of biological activities such as anticancer, antimicrobial, antidiabetic, anti-inflammatory, antileishmanial, and antiviral. Furthermore, Benzothiazole nucleus can function as an efficacious β-amyloid imaging agent .

HY-129133

cis-Miyabenol C	Vitis vinifera cv. Zalema Phenols Plants Vitaceae Source Classification	Drug Isomer
cis-Miyabenol C is an isomer of the resveratrol trimer Miyabenol C, which can be isolated from grape herbs. Miyabenol C is an inhibitor of *β-amyloid* (Aβ) and amyloid β precursor protein (APP) in Alzheimer's disease model mice, and inhibit β-secretase activity without changing the protein level of β-secretase BACE1 .

HY-N7368R

Hibifolin (Standard)	Flavonols Structural Classification Flavonoids other families Phenols Polyphenols Plants Source Classification	Reference Standards Adenosine Deaminase Bacterial Caspase
Hibifolin (Standard) is the analytical standard of Hibifolin. This product is intended for research and analytical applications. Hibifolin is a flavonol glycoside that can be isolated from Helicteres isora. Hibifolin is an inhibitor of adenosine deaminase (ADA) (K_i = 49.92 μM). Hibifolin protects neurons against β-amyloid-induced neurotoxicity. Hibifolin possesses a potent protective activity against cell death induced by aggregated Aβ. Hibifolin can abolish Aβ-induced caspase-3 and caspase-7 activation. Hibifolin induces Akt phosphorylation in cortical neurons. Hibifolin is also a natural sortase A (SrtA) inhibitor (IC₅₀ = 31.2 μM) through direct binding to SrtA protein. Hibifolin attenuates the pathogenic behavior of Staphylococcus aureus including adhesion, invasion, and biofilm formation. Hibifolin improves the survival of pneumonia induced by Staphylococcus aureus in mouse model and alleviates pathological damage. Hibifolin shows a synergistic antibacterial effect with Cefotaxime (HY-A0088A) .

HY-N13064

2,2′,4,4′-Tetrahydroxychalcone	Structural Classification Phenols Polyphenols Morus alba L. Plants Moraceae Source Classification	Drug Derivative Beta-secretase Amyloid-β
2,2′,4,4′-Tetrahydroxychalcone (Compound 18) is a selective and potent BACE1 inhibitor with an IC₅₀ of 0.62 μM. 2,2′,4,4′-Tetrahydroxychalcone is a derivative of Isoliquiritigenin (HY-N0102) found in Glycyrrhiza uralensis. 2,2′,4,4′-Tetrahydroxychalcone can block the β-cutting step of amyloid precursor protein (APP), thereby reducing the production of *β-amyloid* (Aβ) peptide. 2,2′,4,4′-Tetrahydroxychalcone can be used for research of Alzheimer’s disease .

Cat. No.	Product Name	Chemical Structure

HY-16561S

Resveratrol-d4

Resveratrol-d₄ is the deuterium labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-P1363S

β-Amyloid-15N (1-42), human TFA
β-Amyloid- ¹⁵N (1-42), human (TFA) is the ¹⁵N-labledβ-Amyloid (1-42) (TFA). β-Amyloid (1-42), human TFA (Amyloid β-Peptide (1-42) (human) TFA) is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease .

HY-P1363S1

β-Amyloid (1-42), human, Ala(13C3,15N) TFA

β-Amyloid (1-42), human, Ala( ¹³C₃, ¹⁵N) TFA is the ¹³C and ¹⁵N-labeled β-Amyloid (1-42), human (HY-P1363A). β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death .

HY-137315S

TML-6-d3
TML-6-d₃ is the deuterium labeled TML-6. TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ). TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-

HY-P0265AS

β-Amyloid-15N (1-40) TFA
β-Amyloid- ¹⁵N (1-40) (TFA) is the ¹⁵N-labledβ-Amyloid (1-40) (TFA). β-Amyloid (1-40) is a primary protein in plaques found in the brains of patients with Alzheimer's disease .

HY-16561S1

Resveratrol-13C6

Resveratrol- ¹³C₆ is the ¹³C-labeled Resveratrol. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-W004287S

Methyl tridecanoate-d25
Methyl tridecanoate-d₂₅ is the deuterium labeled Methyl tridecanoate. Methyl tridecanoate moderately inhibits β-amyloid aggregation. Methyl tridecanoate weakly inhibits acetylcholinesterase (AChE) .

HY-117259S

Valiltramiprosate-d6

Valiltramiprosate-d₆ (ALZ-801-d₆) is deuterium labeled Valiltramiprosate. ALZ-801 is a potent and orally available small-molecule β-amyloid (Aβ) anti-oligomer and aggregation inhibitor, valine-conjugated proagent of Tramiprosate with substantially improved PK properties and gastrointestinal tolerability compared with the parent compound . ALZ-801 is an advanced and markedly improved candidate for the treatment of alzheimer’s disease .

Host:	Mouse (3) Rabbit (7)
Reactivity:	Human (10) Rat (2) Mouse (8)
Application:	IHC-P (10) ICC/IF (3) IF-Tissue (7) IP (1) DotBlot (2) IHC-F (2) WB (10) ELISA (1)
Isotype:	IgG (7) IgG2a (1) IgG2b (2)
Conjugation:	Non-conjugated (10)
Clonality:	Monoclonal (9) Recombinant (7)
Modification:	Unmodified (9)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86747

	beta-Amyloid 1-42 Antibody (YA6439) beta-amyloid(1-42); A4; AAA; ABETA; ABPP; AD1; Alzheimers Disease amyloid Protein; amyloid B; amyloid beta A4 Protein Precursor; amyloid beta; amyloid of Aging and Alzheimer Disease; APP; APPI; B amyloid; beta APP; Cerebral Vascular amyloid Peptide; CTFgamma; CVAP; PN II; PN2; PreA4; Protease nexin II; A beta; amyloid 1-42.Aβ	WB, IHC-P, IHC-F, IF-Tissue	Human
	beta-Amyloid(1-42) Antibody (YA6439) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to beta-Amyloid(1-42).

HY-P86747A

	beta-Amyloid 1-42 Antibody (YA6439)(PBS only) beta-amyloid(1-42); A4; AAA; ABETA; ABPP; AD1; Alzheimers Disease amyloid Protein; amyloid B; amyloid beta A4 Protein Precursor; amyloid beta; amyloid of Aging and Alzheimer Disease; APP; APPI; B amyloid; beta APP; Cerebral Vascular amyloid Peptide; CTFgamma; CVAP; PN II; PN2; PreA4; Protease nexin II; A beta; amyloid 1-42.Aβ	WB, IHC-P, IHC-F, IF-Tissue	Human
	beta-Amyloid(1-42) Antibody (YA6439) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to beta-Amyloid(1-42).

HY-P86422

	beta-Amyloid Antibody (YA6114) APP; A4; AD1; amyloid beta A4 protein; ABPP; APPI; APP; Alzheimer disease amyloid protein; Cerebral vascular amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II; Aβ	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	beta-Amyloid Antibody (YA6114) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta-Amyloid.

HY-P86875

	FAM38A/PIEZO1 Antibody (YA6568) DHS Fam38a Family with sequence similarity 38 member A KIAA0233 Membrane protein induced by beta-amyloid treatment Mib PIEZ1_HUMAN Piezo-type mechanosensitive ion channel component 1 PIEZO1 Protein FAM38A DHS Fam38a Family with sequence similarity 38 member A KIAA0233 Membrane protein induced by beta-amyloid treatment Mib PIEZ1_HUMAN Piezo-type mechanosensitive ion channel component 1 PIEZO1 Protein FAM38A Protein FAM38B Protein PIEZO1	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	FAM38A/PIEZO1 Antibody (YA6568) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to FAM38A/PIEZO1.

HY-P83753

	beta Amyloid 1-40 Antibody (YA3554) A4 antibody; AAA antibody; ABETA antibody; ABPP antibody; AICD-50 antibody; AICD-57 antibody; AICD-59 antibody; AID(50) antibody; AID(57) antibody; AID(59) antibody; Alzheimer disease amyloid protein antibody; amyloid intracellular domain 50 antibody; amyloid intracellular domain 57 antibody; amyloid intracellular domain 59 antibody; APP antibody; APPI antibody; Beta amyloid protein 42 antibody; Beta APP42 antibody; Beta-APP40 antibody; Beta-APP42 antibody; C31 antibody; Cerebral vascular amyloid peptide antibody; CVAP antibody; Gamma-CTF(50) antibody; Gamma-CTF(57) antibody; Gamma-CTF(59) antibody; PN-II antibody; PreA4 antibody; Protease nexin-II antibody; S-APP-alpha antibody; S-APP-beta antibody; Aβ;	WB, IHC-P, IF-Tissue	Human, Mouse
	beta Amyloid 1-40 Antibody (YA3554) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid 1-40.

HY-P83754

	beta Amyloid 1-42 Antibody (YA3555) A4 antibody; A4_HUMAN antibody; AAA antibody; ABETA antibody; ABPP antibody; AICD-50 antibody; AICD-57 antibody; AICD-59 antibody; AID(50) antibody; AID(57) antibody; AID(59) antibody; Alzheimer disease amyloid protein antibody; amyloid intracellular domain 50 antibody; amyloid intracellular domain 57 antibody; amyloid intracellular domain 59 antibody; APP antibody; APPI antibody; Beta amyloid protein 42 antibody; Beta APP42 antibody; Beta-APP40 antibody; Beta-APP42 antibody; C31 antibody; Cerebral vascular amyloid peptide antibody; CVAP antibody; Gamma-CTF(50) antibody; Gamma-CTF(57) antibody; Gamma-CTF(59) antibody; PN-II antibody; PreA4 antibody; Protease nexin-II antibody; S-APP-alpha antibody; S-APP-beta antibody Aβ	WB, IHC-P, IF-Tissue	Human, Mouse
	beta Amyloid 1-42 Antibody (YA3555) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid 1-42.

HY-P83755

	beta Amyloid Antibody (YA3556) A4 antibody; A4_HUMAN antibody; AAA antibody; ABETA antibody; ABPP antibody; AICD-50 antibody; AICD-57 antibody; AICD-59 antibody; AID(50) antibody; AID(57) antibody; AID(59) antibody; Alzheimer disease amyloid protein antibody; amyloid intracellular domain 50 antibody; amyloid intracellular domain 57 antibody; amyloid intracellular domain 59 antibody; APP antibody; APPI antibody; Beta amyloid protein 42 antibody; Beta APP42 antibody; Beta-APP40 antibody; Beta-APP42 antibody; C31 antibody; Cerebral vascular amyloid peptide antibody; CVAP antibody; Gamma-CTF(50) antibody; Gamma-CTF(57) antibody; Gamma-CTF(59) antibody; PN-II antibody; PreA4 antibody; Protease nexin-II antibody; S-APP-alpha antibody; S-APP-beta antibody; Aβ;	WB, IHC-P, ICC/IF, DotBlot	Human, Mouse
	beta Amyloid Antibody (YA3556) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid.

HY-P83754A

	beta Amyloid 1-42 Antibody (YA3555)(PBS only) A4 antibody; A4_HUMAN antibody; AAA antibody; ABETA antibody; ABPP antibody; AICD-50 antibody; AICD-57 antibody; AICD-59 antibody; AID(50) antibody; AID(57) antibody; AID(59) antibody; Alzheimer disease amyloid protein antibody; amyloid intracellular domain 50 antibody; amyloid intracellular domain 57 antibody; amyloid intracellular domain 59 antibody; APP antibody; APPI antibody; Beta amyloid protein 42 antibody; Beta APP42 antibody; Beta-APP40 antibody; Beta-APP42 antibody; C31 antibody; Cerebral vascular amyloid peptide antibody; CVAP antibody; Gamma-CTF(50) antibody; Gamma-CTF(57) antibody; Gamma-CTF(59) antibody; PN-II antibody; PreA4 antibody; Protease nexin-II antibody; S-APP-alpha antibody; S-APP-beta antibody Aβ	WB, IHC-P, IF-Tissue	Human, Mouse
	beta Amyloid 1-42 Antibody (YA3555) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid 1-42.

HY-P83753A

	beta Amyloid 1-40 Antibody (YA3554)(PBS only) A4 antibody; AAA antibody; ABETA antibody; ABPP antibody; AICD-50 antibody; AICD-57 antibody; AICD-59 antibody; AID(50) antibody; AID(57) antibody; AID(59) antibody; Alzheimer disease amyloid protein antibody; amyloid intracellular domain 50 antibody; amyloid intracellular domain 57 antibody; amyloid intracellular domain 59 antibody; APP antibody; APPI antibody; Beta amyloid protein 42 antibody; Beta APP42 antibody; Beta-APP40 antibody; Beta-APP42 antibody; C31 antibody; Cerebral vascular amyloid peptide antibody; CVAP antibody; Gamma-CTF(50) antibody; Gamma-CTF(57) antibody; Gamma-CTF(59) antibody; PN-II antibody; PreA4 antibody; Protease nexin-II antibody; S-APP-alpha antibody; S-APP-beta antibody; Aβ;	WB, IHC-P, IF-Tissue	Human, Mouse
	beta Amyloid 1-40 Antibody (YA3554) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid 1-40.

HY-P83755A

	beta Amyloid Antibody (YA3556)(PBS only) A4 antibody; A4_HUMAN antibody; AAA antibody; ABETA antibody; ABPP antibody; AICD-50 antibody; AICD-57 antibody; AICD-59 antibody; AID(50) antibody; AID(57) antibody; AID(59) antibody; Alzheimer disease amyloid protein antibody; amyloid intracellular domain 50 antibody; amyloid intracellular domain 57 antibody; amyloid intracellular domain 59 antibody; APP antibody; APPI antibody; Beta amyloid protein 42 antibody; Beta APP42 antibody; Beta-APP40 antibody; Beta-APP42 antibody; C31 antibody; Cerebral vascular amyloid peptide antibody; CVAP antibody; Gamma-CTF(50) antibody; Gamma-CTF(57) antibody; Gamma-CTF(59) antibody; PN-II antibody; PreA4 antibody; Protease nexin-II antibody; S-APP-alpha antibody; S-APP-beta antibody; Aβ;	WB, IHC-P, IF-Tissue, DotBlot	Human, Mouse
	beta Amyloid Antibody (YA3556) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-175524

BChE/MAO-B-IN-2		Alkynes
BChE/MAO-B-IN-2 is a dual inhibitor of BChE (IC₅₀ = 0.05 μM, K_i = 0.01 μM) and MAO-B (IC₅₀ = 0.45 μM, K_i = 0.08 μM) with good blood-brain barrier permeability. BChE/MAO-B-IN-2 exhibits antioxidant activity, including DPPH radical scavenging, CUPRAC copper ion reduction, and superoxide anion scavenging. BChE/MAO-B-IN-2 can be used for the study of Alzheimer's disease (AD) .

Targets Recommended: Amyloid-β

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14176G

Compound E γ-Secretase-IN-1	γ-secretase	Cancer
Compound E (GMP) is a GMP-grade Compound E (HY-14176). GMP-grade small molecules can be used as adjuvant reagents in cell therapy. Compound E is a γ-secretase inhibitor. Compound E inhibits β-amyloid(40), β-amyloid(42), and Notch γ-secretase cleavage with IC₅₀ values of 0.24, 0.37, and 0.32 nM, respectively .

HY-16561G

Resveratrol trans-Resveratrol; SRT501	DNA/RNA Synthesis IKK Autophagy Mitophagy Sirtuin Apoptosis Bacterial Fungal Keap1-Nrf2	Infection Inflammation/Immunology Cancer
Resveratrol (GMP) is Resveratrol (HY-16561) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Resveratrol (trans-Resveratrol; SRT501), a natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, *β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1* activator . Resveratrol is a potent pregnane X receptor (PXR) inhibitor . Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model . Resveratrol increases production of NO in endothelial cells .

HY-16900G

Rolipram	Phosphodiesterase (PDE) Epigenetic Reader Domain Amyloid-β	Neurological Disease Inflammation/Immunology Cancer
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

β-amyloid

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Click Chemistry

GMP Molecules

Natural
Products